As of November 10, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of IO Biotech, Inc. The largest reported stake is Lundbeckfond Invest A/S', at 27.4%. 10 filings are on record since August 19, 2025 (Schedule 13D/A, June 2, 2026).
Sell to companies like IO Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lundbeckfond Invest A/S · Sole voting: 21,851,920 · Shared voting: 0 · Sole dispositive: 21,851,920 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-06-02
- · Holder: Chernett Jorey · Percent: 0% · SCHEDULE 13G/A
- · Holder: Point72 Asset Management, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: HBM Healthcare Investments (Cayman) Ltd. · Percent: 3.3% · SCHEDULE 13G/A
- · Holder: Chernett Jorey · Percent: 6.3% · SCHEDULE 13G/A
IO Biotech, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-19. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 2 filings or notices, latest 2026-01-30 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lundbeckfond Invest A/S | 27.4% | 21,851,920 | SCHEDULE 13D/A, 2026-06-02 | 2026-03-31 |
| Vivo Opportunity, LLC | 4.6% | 3,157,894 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Novo Holdings A/S | 3.3% | 2,469,135 | SCHEDULE 13D/A, 2026-01-23 | 2026-01-21 |
| HBM Healthcare Investments (Cayman) Ltd. | 3.3% | 2,433,943 | SCHEDULE 13G/A, 2026-04-06 | 2026-04-02 |
| 0% | 0 | SCHEDULE 13G/A, 2026-05-20 | 2026-03-31 | |
| Point72 Asset Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind IO Biotech, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on IO Biotech, Inc. and the records around it.
IO Biotech, Inc. elsewhere on the record
- Layoff notices Jan 2026
- Bankruptcy record
Companies that share a holder
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), ALX ONCOLOGY HOLDINGS INC (May 2026), Upstream Bio, Inc. (Nov 2025)
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
Watch IO Biotech, Inc.
Get an email when IO Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on IO Biotech, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on IO Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IO Biotech, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lundbeckfond Invest A/S | 21,851,920 | 0 | 21,851,920 | 0 | SCHEDULE 13D/A, 2026-06-02 |
The latest filing identifies IO Biotech, Inc. by CUSIP 449778109 and gives its principal executive office as Ole Maaloes Vej 3, Copenhagen N (SCHEDULE 13D/A, 2026-06-02).
Purpose of Transaction (Item 4)
Lundbeckfond Invest A/S
Item 4 of the Statement is hereby amended and supplemented as follows: On March 31, 2026, the Issuer ceased operations and filed a voluntary petition for relief (the "Petition") under the provisions of Chapter 7 of Title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware. The assets of the Issuer will be liquidated and claims paid in accordance with the priorities specified in the Bankruptcy Code. Concurrently with the Petition, on March 31, 2026, each member of the Issuer's board of directors, including Christian Elling, resigned from the Board of Directors of the Issuer and all of its committees.Item 4 of the SCHEDULE 13D/A filed 2026-06-02
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-19 | Novo Holdings A/S | 7.3% | SCHEDULE 13D/A |
| 2025-11-05 | Chernett Jorey | 5.3% | SCHEDULE 13G |
| 2025-11-14 | Vivo Opportunity, LLC | 4.6% | SCHEDULE 13G/A |
| 2026-01-23 | Novo Holdings A/S | 3.3% | SCHEDULE 13D/A |
| 2026-02-06 | Point72 Asset Management, L.P. | 5.6% | SCHEDULE 13G |
| 2026-02-13 | Chernett Jorey | 6.3% | SCHEDULE 13G/A |
| 2026-04-06 | HBM Healthcare Investments (Cayman) Ltd. | 3.3% | SCHEDULE 13G/A |
| 2026-05-15 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-05-20 | Chernett Jorey | 0% | SCHEDULE 13G/A |
| 2026-06-02 | Lundbeckfond Invest A/S | 27.4% | SCHEDULE 13D/A |
Questions about who owns IO Biotech, Inc.
Who owns IO Biotech, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of IO Biotech, Inc.: Lundbeckfond Invest A/S (27.4%, Schedule 13D/A, filed 2026-06-02).
When did Lundbeckfond Invest A/S buy into IO Biotech, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lundbeckfond Invest A/S on this page is the Schedule 13D/A, filed 2026-06-02, reporting 27.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for IO Biotech, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 31, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for IO Biotech, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.